Gosselies, Belgium-based Bone Therapeutics SA, the bone cell therapy company addressing unmet medical needs in orthopedics and bone diseases, received €4 million ($4.33 million) as a result of issuing, to existing investors, subordinated bonds with the option to convert. This enables Bone Therapeutics’ bond investors to be repaid in the company’s shares, with a conversion price of €7 per share. This additional financing has been achieved a week after the €11 million financing round. In addition, Bone Therapeutics confirmed the granting of €4.75 million bridge loans provided by commercial banks, detailed in the €11 million financing release from April 29. This follows Sowalfin receiving regulatory approval of the credit assurance that cover the bridge loans. The total amount of committed gross proceeds for both funding operations now amount to €15 million.
Mason, Ohio-based Genetesis Inc., which has developed the noninvasive, biomagnetic Cardioflux imaging, closed strategic investments from Tdk Ventures and an undisclosed Fortune 500 global health care company, completing a $9.2 million series B financing. The round included participation by return investors Cincytech, Ohio Innovation Fund and Mark Cuban. Genetesis also added Sajid Malhotra to its board.
Carlsbad, Calif.-based Genmark Diagnostics Inc., a molecular diagnostics company focused on developing molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, commenced an underwritten public offering of shares of its common stock. Genmark intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Cowen and William Blair are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering. The company plans to use the net proceeds from this offering for general corporate purposes, increasing working capital and the repayment of its existing indebtedness under its loan and security agreement with Solar Capital Partners.
Predictive Oncology Inc., of Minneapolis, a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock, at a purchase price of $1.575 per share, for gross proceeds of approximately $2.2 million in a registered direct offering. Predictive also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. The closing of the offering is expected to occur on or about May 8, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants have an exercise price equal to $1.45 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date. The company currently intends to use up to $487,000 of the net proceeds from the offering to repay certain indebtedness to Oasis Capital LLC, and the remainder for working capital purposes.
Exeter, N.H.-based Vapotherm Inc., a medical technology company focused on the development of its Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress, reported the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26 per share. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price. The offering is expected to close on May 11. Vapotherm intends to use the net proceeds to hire additional sales and marketing personnel and expand marketing programs both in the U.S. and internationally, to make investments in its production capabilities, to fund product development and research and development activities, and for working capital and other general corporate purposes. BofA Securities and William Blair are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager.